Spyre Therapeutics (SYRE) CEO Turtle Cameron sells 15,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Spyre Therapeutics, Inc.'s Chief Executive Officer and director Turtle Cameron reported two open-market sales of common stock. On February 2, 2026, Cameron sold 957 shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87, both coded as open-market sales.

The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. After these sales, Cameron beneficially owned 657,540 shares of common stock, which include shares scheduled to vest over approximately one year and shares acquired under the company’s employee stock purchase plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		957	D	$31.82(2)	671,583(3)(4)	D
Common Stock	02/02/2026		S(1)		14,043	D	$32.87(5)	657,540(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.

4. Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Spyre Therapeutics (SYRE) CEO Turtle Cameron report in this Form 4?

The Form 4 reports that CEO and director Turtle Cameron sold common stock in two open-market transactions on February 2, 2026, under a Rule 10b5-1 plan, and continued to beneficially own 657,540 shares of Spyre Therapeutics common stock after the reported sales.

How many Spyre Therapeutics (SYRE) shares did the CEO sell and at what prices?

Turtle Cameron sold 957 Spyre Therapeutics common shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87. Both were open-market sales, with detailed price ranges available on request as noted in the filing’s footnotes.

Was the Spyre Therapeutics (SYRE) CEO sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the February 2, 2026 transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. Such plans allow pre-established trading instructions, helping separate personal portfolio decisions from day-to-day corporate information flows.

How many Spyre Therapeutics (SYRE) shares does the CEO own after the reported transactions?

After the reported February 2, 2026 sales, CEO Turtle Cameron beneficially owned 657,540 shares of Spyre Therapeutics common stock. This total includes shares scheduled to vest in monthly installments over about one year and shares acquired through the company’s 2016 Employee Stock Purchase Plan.

What do the weighted average prices in the Spyre Therapeutics (SYRE) Form 4 mean?

The weighted average prices of $31.82 and $32.87 reflect multiple trades executed within stated price ranges on February 2, 2026. The filing notes the CEO will provide, upon request, the exact number of shares sold at each individual price level within those ranges.

Does the Spyre Therapeutics (SYRE) Form 4 mention vesting or employee stock purchase plan shares?

Yes. The beneficial ownership figure includes 145,198 common shares that vest in monthly installments over about one year, contingent on continued service, and 633 shares previously acquired under Spyre Therapeutics’ 2016 Employee Stock Purchase Plan on August 15, 2024.